Lupus Therapeutics Market: Size, Share, and Revenue Analysis 2022-2029
The global lupus therapeutics market is experiencing significant growth due to the rising prevalence of lupus disorders worldwide and an increase in research and development (R&D) activities. Lupus, a chronic autoimmune disease, affects millions of people globally, with Systemic Lupus Erythematosus (SLE) being the most common form. Recent studies published in reputable journals have shed light on the link between lupus and COVID-19, further bolstering the market's growth potential.
Read More: https://www.fairfieldmarketresearch.com/report/lupus-therapeuticsmarket
According to a study published in the Lupus Science and Medicine journal in April 2021, the incidence and prevalence of SLE in Europe were estimated to be between 0.3 to 5.1 per 100,000 per year and 6.5 to 85 per 100,000 population, respectively. These numbers highlight the growing burden of lupus and the urgent need for effective therapeutics.
The COVID-19 pandemic has also impacted the lupus therapeutics market positively. Although the exact relationship between COVID-19 and lupus is yet to be fully established, evidence suggests that COVID-19 may trigger systemic lupus erythematosus by creating autoantibodies. A case report from Iran documented a 39-year-old man who developed SLE after exposure to COVID-19. This link has raised awareness and increased the demand for lupus treatments.
The surge in R&D activities is another crucial factor driving the growth of the lupus therapeutics market. Pharmaceutical companies and research institutions are investing heavily in developing novel therapeutics and advanced technologies to address the unmet needs of lupus patients. These initiatives provide promising opportunities for the growth of the market. For example, AstraZeneca recently announced positive results from its TULIP Phase 3 clinical trial program, demonstrating the efficacy and safety of Anifrolumab in reducing SLE symptoms.
The systemic lupus erythematosus (SLE) category holds the largest market share due to the increased number of clinical trial approvals for developing SLE treatments. SLE is a complex autoimmune disease that affects multiple organs, causing tissue damage and a range of clinical symptoms. Manufacturers and players in the lupus therapeutics market are focused on providing effective therapeutics for SLE and other lupus-related illnesses.
North America currently dominates the lupus therapeutics market, primarily driven by the high prevalence of lupus in the region. Major key players in North America are actively engaged in the development of novel technologies, further propelling market growth. In the
United States alone, nearly 1.5 million people have some form of lupus, with SLE accounting for 70% of cases, predominantly affecting women in their adolescent and adult years.
The Asia-Pacific region is expected to witness significant growth during the forecast period due to the region's growing population, increasing healthcare expenditure, and a rising number of research and drug development projects. India, for instance, has recently approved a clinical study for Itolizumab, a drug developed by Biocon Biologics Limited, for the treatment of Lupus Nephritis, a kidney disease associated with SLE.
Leading players in the lupus therapeutics market are actively involved in introducing new products, forging collaborations, alliances, and partnership agreements to enhance their market presence. For example, BenevolentAI, a UK-based clinical-stage AI drug discovery company, expanded its collaboration with AstraZeneca to develop therapeutic medications for the treatment of SLE and heart failure. GlaxoSmithKline plc, a renowned pharmaceutical firm, obtained FDA approval for their medicine BENLYSTA (belimumab) for SLE-related active lupus nephritis.
Key players in the lupus therapeutics market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
As the global lupus therapeutics market continues to expand, it presents significant opportunities for healthcare companies, researchers, and investors to collaborate and develop innovative treatments that improve the quality of life for lupus patients worldwide.
Trending Reports:
https://issuu.com/fairfieldmarket/docs/japan_gas_insulated_transformer_market_to_be nefit_/s/26828790
https://www.pearltrees.com/s/file/preview/300071996/Lupus%20Therapeutics%20Mark et%20Analyzing%20Key%20Drivers%20Restraints%20and%20Growth%20Forecasts %20for%20Business%20Expansion%202022%202029.pdf?pearlId=529049177
https://hackmd.io/@E4v1isUnROG4-prBVaQQGw/B1Hne_UKn
https://dribbble.com/shots/21941947-Lupus-Therapeutics-Market-Exploring-IndustrySize-Share-2029
https://medium.com/@swati_85544/lupus-therapeutics-market-revenue-analysis-andmarket-trends-2022-2029-5a36c0958a40
https://in.pinterest.com/pin/962574120338044322
https://www.click4r.com/posts/g/10736123/
https://www.vingle.net/posts/6447170
https://www.quora.com/profile/Swati-Tiwari-2/What-are-the-growth-opportunitiesand-market-dynamics-in-the-Lupus-Therapeutics-Market-for-the-period-2022-2029-
The-gl https://www.linkedin.com/pulse/lupus-therapeutics-market-revenue-analysisbusiness-growth-shukla/
https://dochub.com/fairfieldmarketresearch3/8adOrbPVQE79gArV24Mj7D/lupustherapeutics-market-exploring-emerging-trends-and-market-dynamics-2022-2029?pg=1
https://writeurl.com/publish/j9dudbl5nvbjoqdaw0it
https://notepin.co/write?id=xwyisgcncghchza
https://www.folkd.com/page/submit.html
Visit Our Blog: https://www.fairfieldmarketresearch.com/blog/the-global-last-miledelivery-market-a-comprehensively-insightful-overview
For further details, please visit www.fairfieldmarketresearch.com.
Contact Fairfield Market Research
London, UK UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Email: sales@fairfieldmarketresearch.com
